Background: Arbekacin (ABK) is an effective aminoglycoside antibiotic agent against methicillin-resistant Staphylococcus aureus (MRSA) used with the recommendation of therapeutic drug monitoring (TDM) in Japanese clinical practice guidelines for TDM1). Since differences in age and body weight (BW) can affect ABK pharmacokinetics (PK), empirical Bayesian methods using population PK (PPK) models with age and/or BW […]
